Long-term Outcome With Prolonged Use of Interferon-alpha Administered Intermittently for Metastatic Renal Cell Carcinoma: A Phase II Study
Anticancer Research · 2023
DOI: 10.21873/anticanres.16431 ↗Kurz gefasst
Klinische Studie (Phase II) in der Zeitschrift Anticancer Research, 2023. Verfasst von Minna Kankuri-Tammilehto und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Oncology and Radiotherapy, Turku University Hospital, Turku, Finland; mikanku@utu.fi. Hauptthemen laut MEDLINE: Carcinoma, Renal Cell, Kidney Neoplasms. Die Arbeit wurde bisher 3-mal zitiert (Crossref).
Abstract (Originalsprache)
BACKGROUND/AIM: Interferon-alpha (IFN-alpha) has shown survival benefits in metastatic renal cell carcinoma (mRCC), but the knowledge about long-term outcome is sparse. Additional knowledge is beneficial because IFN-alpha usage in combination therapy such as immune checkpoint inhibitor for mRCC is an area of interest. This is the longest follow-up concerning IFN-alpha treatment. PATIENTS AND METHODS: A total of 117 metastatic renal cell cancer (mRCC) patients without prior chemotherapy were enrolled between 1994-2002 and followed-up until January 2022. The median follow-up was 18 months. After progression to IFN-alpha, the patients were not treated with tyrosine kinase, mTOR inhibitors or bevacizumab as these were not standard therapies at that time or the patients' performance status was too poor. Mean treatment duration was 11 months. RESULTS: Median overall survival was 19.0 months, 5-year survival rate 16.2%, and 10-year survival rate 9.0%. There were statistically significant differences in survival in response to treatment (log-rank test, p
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Oncology and Radiotherapy, Turku University Hospital, Turku, Finland; mikanku@utu.fi.
- Department of Clinical Genetics, Turku University Hospital, Turku, Finland.
- Institute of Biomedicine, University of Turku, Turku, Finland.
- Institute of Clinical Medicine, Department of Biostatistics, University of Turku, Turku, Finland.
- Department of Oncology and Radiotherapy, Turku University Hospital, Turku, Finland.
- Institute of Clinical Medicine, Department of Clinical Oncology, University of Turku, Turku, Finland.
Zitieren
APA
Kankuri-Tammilehto, M., Perasto, L., Pyrhonen, S., & Salminen, E. (2023). Long-term Outcome With Prolonged Use of Interferon-alpha Administered Intermittently for Metastatic Renal Cell Carcinoma: A Phase II Study. Anticancer Research. https://doi.org/10.21873/anticanres.16431
Vancouver
Kankuri-Tammilehto M, Perasto L, Pyrhonen S, Salminen E. Long-term Outcome With Prolonged Use of Interferon-alpha Administered Intermittently for Metastatic Renal Cell Carcinoma: A Phase II Study. Anticancer Research. 2023. doi:10.21873/anticanres.16431
BibTeX
@article{KankuriTammilehto2023,
author = {Kankuri-Tammilehto, Minna and Perasto, Laura and Pyrhonen, Seppo and Salminen, Eeva},
title = {Long-term Outcome With Prolonged Use of Interferon-alpha Administered Intermittently for Metastatic Renal Cell Carcinoma: A Phase II Study},
journal = {Anticancer Research},
year = {2023},
doi = {10.21873/anticanres.16431}
}
EUVIMED